Abstract
The effect of adriamycin on human and mouse CFUGM was examined at concentrations and times suggested by plasma clearance data derived from the results of a number of published studies. Our results suggest that the high concentrations of drug present in the plasma for short periods of time following infusion are only weakly cytotoxic towards the CFUGM when incubated for similar times. In contrast, there was a considerably greater cytotoxic effect when the drug was examined at low concentrations for periods similar to those described for the terminal phase of adriamycin clearance. The principal metabolite, adriamycinol, was poorly cytotoxic.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Benjamin R. S., Riggs C. E., Jr, Bachur N. R. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Res. 1977 May;37(5):1416–1420. [PubMed] [Google Scholar]
- Burgess A. W., Wilson E. M., Metcalf D. Stimulation by human placental conditioned medium of hemopoietic colony formation by human marrow cells. Blood. 1977 Apr;49(4):573–583. [PubMed] [Google Scholar]
- Byrne P. V., Heit W., Kubanek B. Stimulation of in vitro granulocyte--macrophage colony formation by mouse heart conditioned medium. Br J Haematol. 1978 Oct;40(2):197–204. doi: 10.1111/j.1365-2141.1978.tb03657.x. [DOI] [PubMed] [Google Scholar]
- Chan K. K., Cohen J. L., Gross J. F., Himmelstein K. J., Bateman J. R., Tsu-Lee Y., Marlis A. S. Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treat Rep. 1978 Aug;62(8):1161–1171. [PubMed] [Google Scholar]
- Creasey W. A., McIntosh L. S., Brescia T., Odujinrin O., Aspnes G. T., Murray E., Marsh J. C. Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Res. 1976 Jan;36(1):216–221. [PubMed] [Google Scholar]
- Ehninger G., Stocker H. J., Proksch B., Wilms K. Die Pharmakokinetik von Adriamycin und Adriamycin-Metaboliten. Klin Wochenschr. 1980 Sep 15;58(18):927–934. doi: 10.1007/BF01477050. [DOI] [PubMed] [Google Scholar]
- Legha S. S., Benjamin R. S., Mackay B., Ewer M., Wallace S., Valdivieso M., Rasmussen S. L., Blumenschein G. R., Freireich E. J. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb;96(2):133–139. doi: 10.7326/0003-4819-96-2-133. [DOI] [PubMed] [Google Scholar]
- Ozols R. F., Willson J. K., Weltz M. D., Grotzinger K. R., Myers C. E., Young R. C. Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. Cancer Res. 1980 Nov;40(11):4109–4112. [PubMed] [Google Scholar]
- Robert J., Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Res. 1983 Sep;43(9):4467–4469. [PubMed] [Google Scholar]
- Robert J., Illiadis A., Hoerni B., Cano J. P., Durand M., Lagarde C. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. Eur J Cancer Clin Oncol. 1982 Aug;18(8):739–745. doi: 10.1016/0277-5379(82)90072-4. [DOI] [PubMed] [Google Scholar]
- Rosso R., Ravazzoni C., Esposito M., Sala R., Santi L. Plasma and urinary levels of adriamycin in man. Eur J Cancer. 1972 Aug;8(4):455–459. doi: 10.1016/0014-2964(72)90132-6. [DOI] [PubMed] [Google Scholar]
- Takanashi S., Bachur N. R. Adriamycin metabolism in man. Evidence from urinary metabolites. Drug Metab Dispos. 1976 Jan-Feb;4(1):79–87. [PubMed] [Google Scholar]